10 Jan

Zelboraf Could Boost Roche’s Sales Growth in 2018

WRITTEN BY Daniel Collins

About Zelboraf

Roche’s (RHHBY) Zelboraf (vemurafenib) is indicated for the treatment of individuals with unresectable or metastatic melanoma with the BRAF V600 mutation.

Zelboraf Could Boost Roche’s Sales Growth in 2018

Recent approval

In November 2017, the US Food and Drug Administration (or FDA) approved Roche’s Zelboraf for the treatment of individuals with Erdheim-Chester disease with the BRAF V600 mutation.

Erdheim-Chester disease (or ECD) is a rare disease characterized by an abnormal multiplication of certain WBCs (white blood cells) called histiocytes. A study estimated that there are less than 500 cases of ECD in the US, and that 50% of individuals with ECD have BRAF V600 mutation-positive disease.

FDA approval of Zelboraf is based on the results of the phase two VE-BASKET trial. The concluding results from the phase two VE-BASKET trial demonstrated a 54.5% overall response rate (or ORR).

Previously, in 2011, Zelboraf monotherapy received FDA approval for the treatment of individuals with metastatic melanoma with BRAF V600 mutation.

In September 2017, Roche presented the results from its phase three BRIM8 trial. Roche conducted the phase three BRIM8 trial to evaluate the safety and efficacy of Zelboraf as the adjuvant (after surgery) treatment of individuals with completely resected BRAF V600 mutation-positive melanoma.

Roche’s phase three BRIM8 trial was conducted in two cohorts: cohort 1 (stage IIC-IIIB) and cohort 2 (stage IIIC) melanoma patients. The phase three BRIM8 trial did not achieve its primary endpoint of significant reduction in the risk of recurrence or disease-free survival in patients with stage IIIC melanoma or cohort 2. However, in cohort 1, Zelboraf demonstrated 46% reduction in risk of recurrence.

Zelboraf’s peer in the metastatic melanoma with BRAF V600 mutation market is Novartis’s (NVS) Tafinlar+Mekinisk. In 3Q17, Tafinlar+Mekinist generated revenues of $224 million. Other notable metastatic melanoma drugs include Merck’s (MRK) Keytruda and Bristol-Myers Squibb’s (BMY) Yervoy. The growth in sales of Roche’s Zelboraf could boost the Vanguard FTSE Developed Markets ETF (VEA). Roche makes about ~2.1% of VEA’s total portfolio holding.

Latest articles

19 Jul

Afya's IPO Sees Strong Listing Gains

WRITTEN BY Mohit Oberoi, CFA

Afya (AFYA) listed on the Nasdaq Global Select Market on July 19. The company priced its IPO at $19 per share.

19 Jul

What to Watch For in Amazon's Q2 Earnings

WRITTEN BY Sanmit Amin

e-Commerce giant Amazon (AMZN) is scheduled to report its second-quarter earnings results after the closing bell on July 25.

19 Jul

Barrick Gold Reaches Deal to Buy Acacia Mining

WRITTEN BY Anuradha Garg

After a long standoff, Barrick Gold (GOLD) and Acacia Mining (ABGLF) have reached an agreement.

19 Jul

Comcast Shares Pop on Goldman's Optimism

WRITTEN BY Ruchi Gupta

Comcast (CMCSA) shares popped after Goldman Sachs issued a positive note on the company recently. Goldman upgraded its rating for Comcast to "buy" from "hold."

19 Jul

Why Analysts Are Bearish on Netflix Stock

WRITTEN BY Aditya Raghunath

Netflix stock fell over 10.0% on Thursday and is down 0.5% today as well.

On Thursday, pet retailer Chewy (CHWY) reported its first-quarter results after the market closed. The company reported its earnings for the first time.